



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 12 Nov 2018 (#35)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices

- **Notice of Change in Receipt Date for the Emerging Global Leader Award (K43) (Independent Clinical Trial Not Allowed) ([NOT-TW-18-009](#)) John E. Fogarty International Center**

1. Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-NS-19-010](#))

Type: UG3/UH3

Application Due Date: January 4, 2019 and March 6, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

Budget: NIH intends to fund an estimated 6-8 awards, corresponding to a total cost of \$6 million for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets must reflect the actual needs of the proposed project. The UG3 phase budget, a maximum of 2 years, should not exceed \$500K direct cost per year. The UH3 phase budget should not exceed \$1.5M direct cost per year. Budgets for all years including both phases must be provided. The total duration may not exceed 5 years.

2. NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PA-19-052](#))

Type: R03

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s). **Note:** Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest

Budget: Application budgets are limited to \$50,000 in direct costs per year. The total project period may not exceed two years.

3. NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([PA-19-053](#))

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Note: Not all NIH Institutes and Centers (ICs) participate in Parent Announcements. Applicants should carefully note which ICs participate in this announcement and view their respective areas of research interest

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

4. NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-054\)](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see [Related Notices](#)) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

5. Research Project Grant (Parent R01 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-055\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see [Related Notices](#)) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

6. Research Project Grant (Parent R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-19-056\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s)

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

7. Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21 Clinical Trials Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-059\)](#)

Type: R21

Application Due Date: December 13, 2018, December 13, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports planning, design and initial pilots for locally relevant and catalytic research on non-communicable diseases (NCDs) or injury in low and middle-income countries (LMICs). Research addressing multiple NCDs and their risk factors and research addressing NCDs as comorbidities for/with infectious diseases including HIV/AIDS is encouraged. Only scientists from the LMIC institutions are eligible to apply as the contact PI/PD. Income categories used are defined by the World Bank at <http://data.worldbank.org/about/country-classifications/country-and-lending-groups>. Research activities under this FOA are expected to inform the development of comprehensive research programs that contribute to the long-term goals of building sustainable research capacity in LMICs to address NCDs and injury throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work may also contribute to developing a base for research networking and evidence-based policy beyond the specific research project. For applications on any research topic related to the brain, nervous system, mental health and substance abuse please see the companion FOA: PAR-18-836 "Global Brain and Nervous System Disorders Research Across the Lifespan (R21)". Applications on those topics are not appropriate for this FOA.

Budget: The combined budget for direct costs for the two-year period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

8. NINR Clinical Trial Planning Grant (R34 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-19-060\)](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to provide time and support for the applicant to develop and finalize plans for the design and execution of investigator-initiated clinical trials that are highly relevant to the NINR mission. Activities supported by this planning grant must include feasibility and pilot studies that inform the intervention viability and/or the trial design.

Budget: Application budgets are limited to \$250,000 in direct costs over the 2-year period with no more than \$150,000 in direct costs allowed in any single year.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Christa* • Tel: 9838 • Email: cde.vries@sun.ac.za